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Abstract
Background: Tricuspid regurgitation (TR) is common in patients with mitral valve disease; however, there are no
straightforward, rapidly determinably criteria available for deciding whether TR repair should be performed during
mitral valve replacement. The aim of our retrospective study was to identify a simple and fast criterion for
determining whether TR repair should be performed in patients undergoing mitral valve replacement.
Methods: We reviewed the records of patients who underwent mitral valve replacement with or without (control)
TR repair (DeVega or Kay procedure) from January 2005 to December 2008. Preoperative and 2-year postoperative
echocardiographic measurements included right ventricular and atrial diameter, interventricular septum size, TR
severity, ejection fraction, and pulmonary artery pressure.
Results: A total of 89 patients were included (control, n = 50; DeVega, n = 27; Kay, n = 12). Demographic and
clinical characteristics were similar between groups. Cardiac variables were similar between the DeVega and Kay
groups. Right atrium and ventricular diameter and ejection fraction were significantly decreased postoperatively
both in the control and operation (DeVega + Kay) group (P < 0.05). Pulmonary artery pressure was significantly
decreased postoperatively in-operation groups (P < 0.05). Our findings indicate that surgical intervention for TR
should be considered during mitral valve replacement if any of the following preoperative criteria are met: right
atrial transverse diameter > 57 mm; right ventricular end-diastolic diameter > 55 mm; pulmonary artery pressure >
58 mmHg.
Conclusions: Our findings suggest echocardiography may be used as a rapid and simple means of determining
which patients require TR repair during mitral valve replacement.
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Background
Approximately 30% of patients with mitral stenosis have
at least moderate tricuspid regurgitation (TR) [1,2].
Further, findings from several studies have demonstrated
that 23% to 37% of patients develop serious TR after
mitral valve replacement for rheumatic heart disease
[3,4]. Matsuyama et al. [5] have also reported that 37%
of patients who had Grade II TR before surgery devel-
oped > moderate TR after mitral valve replacement.
This percentage is even higher for patients who receive
surgical intervention for ischemic mitral valve disease,
with up to 74% developing moderate to severe TR
within 2 years of surgery [6,7]. The high prevalence of
TR after mitral valve replacement is of clinical interest
given that TR can result in heart failure, cardiac
cachexia, and a general poor prognosis.
Over the last decade, a number of studies have exam-
ined the value of correcting TR in patients undergoing
mitral valve repair [8-11]. Dreyfus et al. [12] found that
both hospital mortality and actuarial survival were
increased, although not significantly so, in patients who
underwent mitral valve replacement and tricuspid annulo-
plasty compared with patients who underwent mitral valve
replacement alone. Further, the proportion of patients
with > Grade II TR was significantly lower (2%) after
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any medium, provided the original work is properly cited.mitral valve replacement and tricuspid annuloplasty com-
pared with mitral valve replacement alone (48%). In
another study, De Bonis et al. [13] found that 12% of
patients with TR caused by mitral regurgitation who
underwent mitral valve repair and tricuspid annuloplasty
experienced ≥ Grade III TR 2 years after surgery. Interest-
ingly, Koukoui et al. [14] reported that TR was uncommon
in patients with mitral valve prolapse after surgery in
patients who did not have TR before treatment.
Clearly, some patients are more likely to benefit from
tricuspid annuloplasty during mitral valve replacement.
Both the American College of Cardiology/American
Heart Association (ACC/AHA) [15] and the European
Society of Cardiology (ESC) [16] recommend (Class I)
performing mitral valve surgery with tricuspid annulo-
plasty for patients with severe TR. The ESC also recom-
mends (Class IIa) simultaneous tricuspid annuloplasty
for patients with a tricuspid valve diameter > 40 mm or
moderate TR [16]. In contrast, the ACC/AHA recom-
mends (Class IIb) simultaneous tricuspid annuloplasty
for patients with moderate or mild TR [15]. The ESC
also recommends (Class IIa) tricuspid annuloplasty
before right heart failure and severe pulmonary hyper-
tension if there are isolated symptoms of TR after left
heart valve surgery [16]. Antunes and Barlow [8] have
suggested that tricuspid annuloplasty should be per-
formed for patients with greater than mild TR and at
least one of the following: rheumatic valve disease; tri-
cuspid valve annulus diameter > 21 mm/m
2;e x p a n s i o n
of the right heart chamber; expansion of the inferior
vena cava; or right ventricular overload.
The purpose of this retrospective study was to identify
a simple and fast criterion for determining whether TR
repair should be performed in patients undergoing
mitral valve replacement.
Methods
Patients
The records of 89 consecutive patients who underwent
mitral valve replacement surgery from January 2005 to
December 2008 and completed 2 years of follow-up
were retrospectively reviewed. Of the 89 patients, 39
also underwent tricuspid valve surgery for the treatment
of TR (n = 27, DeVega procedure; n = 12, Kay proce-
dure). The 50 patients who did not undergo tricuspid
valve surgery served as the control group. Patients who
were > 65 years of age received a biological valve for
mitral valve replacement, whereas patients who were <
65 years of received a mechanical valve for mitral valve
replacement. Inclusion criteria: mitral valve disease with
necessary replacement; tricuspid valve disease with func-
tional changes; mitral valve disease combined with tri-
cuspid valve disease. Exclusion criteria: combined with
aortic valve disease or other cardiac diseases (e.g.
coronary heart disease); tricuspid valve autologous dis-
eases (e.g. caused by rheumatic diseases etc.); mitral
valve disease without necessary replacement. This study
was approved by Ethics Committee of The First
Affiliated Hospital of Soochow University.
Surgery
The requirement for tricuspid valve surgery was deter-
mined with reference to the severity of TR. The severity
of TR was determined intraoperatively using the water
test, performed after mitral valve replacement and cardi-
o v e r s i o n .M i l dT Rw a si n d i c a t e db yt h er i g h tv e n t r i c l e
remaining fully filled after a cardiac cycle; moderate TR
was indicated by the right ventricle remaining ≥ 50%
filled after a cardiac cycle; and severe TR was indicated
by 0% right ventricular filling after a cardiac cycle. If TR
was mild, surgical intervention was not performed
(these patients were included in the control group).
Patients with moderate TR underwent Kay annuloplasty
and patients with moderate to severe or severe TR
underwent DeVega annuloplasty. In brief, for Kay annu-
loplasty 1-2 mattress sutures with double-headed nonin-
vasive stitches were placed along the junction between
the anterior mitral valve leaflet and the posterior mitral
valve leaflet, and at the posterior mitral valve ring.
Spacer blocks were applied for both insertion and with-
drawal of the needle and the valve annulus was shor-
tened after ligation. For DeVega annuloplasty, a double
layer cross-over continuous suture with double-headed
noninvasive stitches along the valve rings of the anterior
leaflet and the posterior leaflet was placed. Spacer blocks
were applied for both insertion and withdrawal of the
needle, and the stitches were tightened and ligated to
shorten the dilated posterio rv a l v er i n g sa tt h eb a s eo f
the posterior and anterior leaflets. All surgeries were
performed by the same surgeon.
Measurements
Preoperatively, all patients underwent echocardiographic
examinations. The apical 4-chamber view was used to
determine the diameter of the right ventricles and atria,
the size of the interventricular septum, the degree of
TR, and ejection fraction. Pulmonary artery pressure
was also assessed. All examinations were performed by
the same radiologist. The degree of TR was evaluated
using the regurgitation jet area method [17]. The maxi-
mum regurgitation area was determined from cross-sec-
tional images, and the ratio between this area and the
area of the right atrium was calculated. The severity of
TR was defined by the following ratios: < 20% = mild;
20-40% = moderate; > 40% = severe. All patients were
followed up for a minimum of 2 years. The same radiol-
ogist repeated the echocardiographic examinations 2
years after surgery to determine postoperative changes.
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Demographic data are presented as mean ± standard
deviation (SD) for age and number (percentage) for
categorical variables. Data were compared between
groups by one-way analysis of variance for age and Fish-
er’s exact test for other categorical variables. Cardiac
variables (including pulmonary artery pressure) are sum-
marized as mean ± SD. Between group comparisons
(control vs operation; De Vega vs Kay) and preoperative
vs postoperative comparisons were made using two-
sample t-test. Analysis of covariance was performed to
compare cardiac variables among the 3 groups post-
operatively if the variables were imbalanced preopera-
tively. The ordinal data, TR severity, are summarized as
number (%) and were compared by Kruskal-Wallis test
(among all 3 groups) with a post-hoc pair-wise compari-
son, Mann-Whitney U test (De Vega vs Kay groups). All
statistical assessments were two-tailed. Statistical signifi-
cance was indicated by P < 0.05. An adjusted statistical
significance level (P < 0.0167 [0.05/3]) was used for
post-hoc pair-wise comparisons. Statistical analyses were
performed using SPSS 15.0 statistical software (SPSS
Inc, Chicago, IL).
Results
Patient demographics were similar between groups
(Table 1). Patients were generally aged in their late 40’s/
early 50’s and were predominantly (≥ 60%) female. Most
(52-75%) patients had a history of rheumatic heart
disease or mitral insufficiency (25-44%). There were no
significant between group differences in New York
Heart Association functional class before surgery or in
the type of bicuspid valve replacement.
Table 2 summarizes the pre- and postoperative car-
diac data for the control and operation (DeVega and
Kay) groups. For both groups, right atrium inner dia-
meter, right ventricle inner diameter, and ejection frac-
tion were significantly decreased 2 years after surgery
(all P < 0.05). Pulmonary artery pressure was signifi-
cantly decreased 2 years after surgery in the operation
group only (P < 0.05).
Table 3 summarizes the pre- and postoperative car-
diac data for the DeVega and Kay operation groups.
There were no significant between group differences for
any of the variables assessed. For both groups, right
atrium inner diameter, right ventricle inner diameter,
and pulmonary artery pressure were significantly
decreased 2 years after surgery (all P < 0.05). Ejection
fraction was significantly decreased 2 years after surgery
in the DeVega operation group only (P < 0.05).
Table 4 summarizes TR severity for each group, both
pre- and postoperatively. There was a significant differ-
ence in TR severity preoperatively (P < 0.001). All
patients in the control had minor TR, whereas all
patients in the DeVega and Kay groups had moderate or
severe TR. There was no significant difference in TR
severity postoperatively. The vast majority (≥ 83%) of
patients in each group had minor TR postoperatively.
Table 1 Patient demographic data
Variables Control group
(n = 50)
DeVega group
(n = 27)
Kay group
(n = 12)
P
Age (years) 53.0 ± 13.6 49.8 ± 10.9 49.7 ± 15.9 0.511
Sex 0.327
Male 20 (40) 9 (33) 2 (17)
Female 30 (60) 18 (67) 10 (83)
Medical history 0.496
Rheumatic heart disease 26 (52) 18 (67) 9 (75)
Mitral insufficiency 22 (44) 9 (33) 3 (25)
Coronary heart disease 2 (4) 0 (0) 0 (00)
Heart function before surgery (NYHA class) 0.317
I 20 (40) 9 (33) 4 (33)
II 22 (44) 14 (52) 3 (25)
III 8 (16) 4 (15) 5 (42)
Bicuspid valve replacement 0.167
Mechanical prosthesis 33 (66) 23 (85) 8 (67)
Biovalve 17 (34) 4 (15) 4 (33)
NYHA, New York Heart Association.
Continuous data are presented as mean ± standard deviation and were compared by one-way analysis of variance. Categorical data are presented as number
(percentage) and were compared by Fisher’s exact test.
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To date, there is no quantitative index available for
determining whether surgery for TR is necessary in
patients undergoing mitral valve replacement. In the
present study, we performed echocardiographic assess-
ments to examine changes in cardiac parameters before
and after mitral valve replacement with or without TR
repair and to identify criteria for determining the need
for TR surgery during mitral valve replacement. Of
note, patients who underwent mitral valve replacement
with concurrent tricuspid valve surgery for TR (both the
DeVega and Kay procedure) had marked postoperative
reductions in TR severity. Few patients in the control
group (mild TR and mitral valve replacement alone)
experienced an increase in TR severity after surgery.
Our preoperative echocardiographic findings suggest
that surgical intervention for TR is not required for
patients with a preoperative right atrial transverse dia-
meter < 40 mm. If this diameter is > 55 mm, surgical
intervention is warranted, whereas if the diameter is
between 40 and 55 mm, no definitive determination can
be made. Surgical intervention for TR is also not war-
ranted for patients with a preoperative right ventricular
end-diastolic diameter < 40 mm, but is warranted if this
diameter is > 53 mm. If the preoperative right ventricu-
lar end-diastolic diameter is between 40 and 53 mm, no
definitive determination can be made. Our findings also
suggest that surgical intervention for TR is not war-
ranted for patients with a preoperative pulmonary artery
pressure < 33 mmHg, but is warranted if this pressure is
> 57 mmHg. If the preoperative pulmonary artery pres-
sure is between 33 and 57 mmHg, no definitive determi-
nation can be made. For patients with right ventricular
end diastolic diameter, right atrial transverse diameter,
and pulmonary artery pressure values between the high
Table 2 Pre- and postoperative cardiac data for the
control and operation groups
Variable Control
group
(n = 50)
Operation
group
a
(n = 39)
Right atrium inner diameter (mm)
Preoperative 38.92 ± 3.66 57.21 ± 3.24
2-years postoperative 38.10 ± 3.89† 48.64 ± 3.27†
Right ventricle inner diameter (mm)
Preoperative 39.12 ± 3.46 54.95 ± 3.19
2-years postoperative 37.10 ± 3.57† 46.18 ± 3.48†
Interventricular septum thickness
(mm)
Preoperative 9.22 ± 1.66 8.74 ± 1.27
2-years postoperative 9.16 ± 2.00 8.82 ± 1.07
Pulmonary artery pressure (mmHg)
Preoperative 32.14 ± 1.99 57.92 ± 2.91
2-years postoperative 31.96 ± 2.40 31.46 ± 2.83†
Ejection fraction (%)
Preoperative 0.63 ± 0.09 0.63 ± 0.11
2-years postoperative 0.59 ± 0.09† 0.56 ± 0.10†
a The operation group included patients who underwent DeVega and Kay
procedures.
Data are presented as mean ± SD.
† P < 0.05, statistically significant difference between preoperative and
postoperative values (paired t-test).
Table 3 Pre- and postoperative cardiac data for the De
Vega and Kay groups
Variable DeVega
group
(n = 27)
Kay group
(n = 12)
P
Right atrium inner diameter (mm)
Preoperative 57.33 ± 3.08 56.92 ± 3.70 0.716
2-years postoperative 49.11 ± 2.99† 47.58 ±
3.73†
0.737
Right ventricle inner diameter (mm)
Preoperative 54.96 ± 3.01 54.92 ± 3.70 0.967
2-years postoperative 46.07 ± 3.40† 46.42 ±
3.80†
0.781
Interventricular septum thickness
(mm)
Preoperative 8.93 ± 1.30 8.33 ± 1.16 0.183
2-years postoperative 8.85 ± 1.06 8.75 ± 1.14 0.788
Pulmonary artery pressure (mmHg)
Preoperative 57.41 ± 2.19 59.08 ± 3.97 0.191
2-years postoperative 31.33 ± 3.26† 31.75 ±
1.55†
0.591
Ejection fraction (%)
Preoperative 0.63 ± 0.11 0.62 ± 0.10 0.803
2-years postoperative 0.56 ± 0.10† 0.59 ± 0.09 0.452
Data are presented as mean ± SD.
† P < 0.05, statistically significant difference between preoperative and
postoperative values (paired t-test).
Table 4 Comparison of tricuspid regurgitation severity
Severity of
tricuspid
regurgitation
Control group
(n = 50)
DeVega group
(n = 27)
Kay group
(n = 12)
P
Preoperative < 0.001*
Minor 50 (100) 0 (0) 0 (0)
Moderate 0 (0) 10 (37) 11 (92)
Severe 0 (0) 17 (63) 1 (8)
Postoperative 0.736
Minor 45 (90) 25 (93) 10 (83)
Moderate 4 (8) 0 (0) 2 (17)
Severe 1 (2) 2 (7) 0 (0)
Data are presented as number (percentage). Difference among three groups
was compared using Kruskal-Wallis test; Difference between two groups (post-
hoc pair-wise comparisons) was compared using Mann-Whitney U test.
*P < 0.05, statistically significant difference among three groups (Kruskal-Wallis test).
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TR should be considered when evaluating the need for
tricuspid valve surgery.
Expansion of the tricuspid annulus is an important factor
affecting TR. A normal tricuspid annulus is shaped like
saddle, with the highest point located at the junction
between the anterior leaflet and the posterior leaflet. How-
ever, with increasing TR severity, the tricuspid annulus
may expand, becoming flat and round [6,18,19]. Antunes
and Barlow reported that during the course of rheumatic
disease, rheumatoid process is directly related to TR, which
weakens the annulus and causes its expansion [8]. The dia-
meter of a normal tricuspid annulus (2.8 ± 0.5 cm) can be
obtained by echocardiography using an apical 4-chamber
view and measuring the distance between the base of the
septal leaflet and that of the posterior leaflet [20]. Sugimoto
et al. [21] reported that there was an excellent correlation
between the diameter of the tricuspid valve and the volume
o fT R .A c c o r d i n g l y ,c u r r e n ttricuspid valvuloplasty is
mainly focused on annuloplasty and includes the DeVega
procedure, the Kay procedure, and procedures using annu-
loplasty rings (eg, Carpentier ring). In the current study,
patients with moderate TR underwent Kay annuloplasty
and patients with moderate to severe or severe TR under-
went DeVega annuloplasty. Of note, both procedures were
equally effective, with low rates of medium and severe TR
found 2 years after surgery.
The primary limitations of this study are the relatively
s m a l ls a m p l es i z ea n dt h es h o r tl e n g t ho ff o l l o w - u p .O f
note, there were only 12 patients in the Kay operative
group. A larger scale study, with an increased number
of patients and a longer duration of follow-up is needed
to confirm the findings reported herein.
Conclusion
In conclusion, we suggest that echocardiography can be
employed to determine whether patients with TR
require surgical intervention for TR during mitral valve
replacement. Specifically, we suggest that measures of
right atrial transverse diameter, right ventricular end-
diastolic diameter, and pulmonary artery pressure can
be used as indicators to determine the need for surgical
intervention. We will further do the follow-up to esti-
mate the operative results using this method.
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